Mankind Pharma (MANKIND) Aktienübersicht
Mankind Pharma Limited entwickelt, produziert und vermarktet pharmazeutische Formulierungen und Produkte der Gesundheitsfürsorge hauptsächlich in Indien und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für MANKIND festgestellt.
MANKIND Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mankind Pharma Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹2,507.50 |
| 52-Wochen-Hoch | ₹2,716.50 |
| 52-Wochen-Tief | ₹1,909.70 |
| Beta | 0.45 |
| 1 Monat Veränderung | 5.31% |
| 3 Monate Veränderung | 20.70% |
| 1 Jahr Veränderung | -7.01% |
| 3 Jahre Veränderung | 36.11% |
| 5 Jahre Veränderung | n/a |
| Veränderung seit IPO | 76.30% |
Aktuelle Nachrichten und Updates
Analyseartikel • 10h
Analysts Are Updating Their Mankind Pharma Limited (NSE:MANKIND) Estimates After Its Yearly Results
The yearly results for Mankind Pharma Limited ( NSE:MANKIND ) were released last week, making it a good time to revisit...
Narrative-Update • Jun 29
MANKIND: Higher Growth Assumptions Will Be Offset By Weaker Profitability
Analysts have lifted their fair value estimate for Mankind Pharma from ₹1,990 to about ₹2,062, reflecting updated assumptions that combine higher revenue growth expectations with slightly lower profit margin forecasts and a modestly reduced future P/E multiple. What's in the News Mankind Pharma has scheduled a board meeting on May 19, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider several corporate actions.
Narrative-Update • Jun 15
MANKIND: Subsidiary Reshuffle And Higher P/E Assumptions Will Support Re Rating
Analysts have raised the price target for Mankind Pharma slightly to ₹3,100 from ₹3,085.68, reflecting updated assumptions regarding a higher future P/E multiple, as well as adjusted expectations for revenue growth, profit margins, and the discount rate. What's in the News Board meeting on May 19, 2026 to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, consider realignment of security cover for existing non convertible debentures after redemption of ₹12,50,00,00,000 of NCDs on April 16, 2026, review management changes, and evaluate additional investment in subsidiaries.Recent updates
Analyseartikel • 10h
Analysts Are Updating Their Mankind Pharma Limited (NSE:MANKIND) Estimates After Its Yearly Results
The yearly results for Mankind Pharma Limited ( NSE:MANKIND ) were released last week, making it a good time to revisit...Narrative-Update • Jun 29
MANKIND: Higher Growth Assumptions Will Be Offset By Weaker Profitability
Analysts have lifted their fair value estimate for Mankind Pharma from ₹1,990 to about ₹2,062, reflecting updated assumptions that combine higher revenue growth expectations with slightly lower profit margin forecasts and a modestly reduced future P/E multiple. What's in the News Mankind Pharma has scheduled a board meeting on May 19, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider several corporate actions.Narrative-Update • Jun 15
MANKIND: Subsidiary Reshuffle And Higher P/E Assumptions Will Support Re Rating
Analysts have raised the price target for Mankind Pharma slightly to ₹3,100 from ₹3,085.68, reflecting updated assumptions regarding a higher future P/E multiple, as well as adjusted expectations for revenue growth, profit margins, and the discount rate. What's in the News Board meeting on May 19, 2026 to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, consider realignment of security cover for existing non convertible debentures after redemption of ₹12,50,00,00,000 of NCDs on April 16, 2026, review management changes, and evaluate additional investment in subsidiaries.
Narrative-Update • Jun 01
MANKIND: Higher Future Multiple And Subsidiary Exit Will Support Further Upside
Analysts have raised their fair value estimate for Mankind Pharma from ₹2,515.74 to ₹2,653.40, citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News Mankind Pharma has scheduled a board meeting on May 19, 2026, at 15:10 IST to consider standalone and consolidated audited financial results for the quarter and year ended March 31, 2026; review security cover for existing non convertible debentures after the redemption of ₹1,250 crore of NCDs on April 16, 2026; consider management changes; and evaluate an additional investment in its subsidiary, Mankind Medicare Private Limited (source: company board agenda).Analyseartikel • May 22
Analysts Have Made A Financial Statement On Mankind Pharma Limited's (NSE:MANKIND) Yearly Report
It's been a good week for Mankind Pharma Limited ( NSE:MANKIND ) shareholders, because the company has just released...Narrative-Update • May 05
MANKIND: Subsidiary Exit And Firm Margins Will Support Further Upside
Mankind Pharma's analyst price target has been adjusted slightly higher from ₹2,506.53 to ₹2,515.74 as analysts update their assumptions around revenue growth, profit margin and forward P/E expectations. What's in the News The board is scheduled to meet on April 13, 2026, at 15:00 Indian Standard Time to review corporate matters, including the subsidiary structure (company filing).Narrative-Update • Apr 20
MANKIND: Subsidiary Closure Decision Will Support Future Re Rating Potential
Analysts have made a slight trim to the price target for Mankind Pharma, with fair value moving from ₹3,100.00 to about ₹3,085.68 as they refresh assumptions around revenue growth, profit margins, and future P/E levels. What's in the News The board plans to meet on Apr 13, 2026, at 15:00 Indian Standard Time to review and approve the closure of Mankind Pharma Lanka Private Limited, the wholly owned subsidiary in Sri Lanka, following changes in local regulatory requirements (Key Developments).Narrative-Update • Apr 06
MANKIND: Upcoming Results And Solid Margins Will Support Further Upside
Analysts have cut their price target on Mankind Pharma by ₹30 to reflect slightly lower assumptions for revenue growth, profit margins and future P/E multiples, resulting in a modest reset in fair value expectations. What's in the News A board meeting is scheduled on Feb 3, 2026 at 15:00 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, along with the Limited Review Report (Key Developments).Narrative-Update • Mar 22
MANKIND: Upcoming Board Review And Steady Assumptions Will Support Bullish Re Rating
Analysts have kept Mankind Pharma's fair value estimate unchanged at ₹3,100 per share, citing slightly higher assumptions for revenue growth at 14.04% and profit margin at 21.31%, along with a marginally lower future P/E of 41.44x. What's in the News Board meeting scheduled for Feb 03, 2026 at 15:00 IST to review and approve unaudited standalone financial results for the quarter ended Dec 31, 2025, along with the Limited Review Report (company filing).Narrative-Update • Mar 08
MANKIND: Upcoming Results And Firmer Margins Will Support Bullish Re-Rating
Analysts have slightly reduced their fair value estimate for Mankind Pharma to ₹3,100 from ₹3,110, reflecting updated assumptions around modestly different revenue growth, margins, and future P/E expectations. What's in the News A board meeting is scheduled on February 3, 2026, at 15:00 Indian Standard Time to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with the Limited Review Report (Key Developments).Narrative-Update • Feb 22
MANKIND: Upcoming Results Will Support Further Upside Despite Modest Assumption Cuts
Analysts have trimmed their price target for Mankind Pharma from about ₹2,631 to about ₹2,537. This reflects slightly lower assumptions for revenue growth, profit margins and future P/E multiples, alongside a modestly reduced discount rate.Narrative-Update • Feb 08
MANKIND: Fair Value Outlook Will Reflect Lower Growth And Higher Margins
Analysts have trimmed their fair value estimate for Mankind Pharma from ₹2,150 to ₹1,990, citing updates to revenue growth, profit margin and assumed future P/E levels in their revised models. What's in the News Mankind Pharma has scheduled a board meeting on Feb 03, 2026, at 15:00 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, along with the Limited Review Report (Key Developments).Narrative-Update • Jan 24
MANKIND: Firmer Margins And Upcoming Results Will Support Future Bullish Re-Rating
Analysts have trimmed their fair value estimate for Mankind Pharma from ₹3,260 to ₹3,110, citing slightly softer revenue growth expectations, partly offset by firmer profit margin and P/E assumptions. What's in the News Board meeting scheduled on Feb 03, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Narrative-Update • Jan 10
MANKIND: Rising Margins And Upcoming Results Will Support Further Upside
Analysts have trimmed their price target for Mankind Pharma from ₹2,699 to ₹2,631, citing updated assumptions that reflect slightly different expectations for revenue growth, profit margins and future P/E multiples. What's in the News Mankind Pharma has scheduled a board meeting on Nov 06, 2025 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).Analyseartikel • Dec 14
Does Mankind Pharma (NSE:MANKIND) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative-Update • Dec 14
MANKIND: Strong Profitability Outlook Will Support Future Bullish Re-Rating
Narrative Update Analysts have modestly trimmed their fair value estimate for Mankind Pharma to ₹3,260 from ₹3,300, reflecting slightly lower expected revenue growth and valuation multiples, partly offset by an improved profit margin outlook. What's in the News Board meeting scheduled for November 6, 2025, to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments) Valuation Changes Fair Value Estimate reduced slightly to ₹3,260 from ₹3,300, reflecting a modest downward revision in intrinsic value.Narrative-Update • Nov 27
MANKIND: Rising Margins And Upcoming Results Will Drive Further Upside
Analysts have slightly reduced their fair value estimate for Mankind Pharma from ₹2,725.59 to ₹2,699.12. They cite minor adjustments in projected revenue growth and profit margins as influencing factors.Analyseartikel • Nov 09
Analysts Are Updating Their Mankind Pharma Limited (NSE:MANKIND) Estimates After Its Second-Quarter Results
Last week, you might have seen that Mankind Pharma Limited ( NSE:MANKIND ) released its quarterly result to the market...Narrative-Update • Nov 08
MANKIND: Expansion Into Russia And Rising Margins Will Drive Upside
Analysts have revised the fair value estimate for Mankind Pharma down from ₹2,799.65 to ₹2,725.59. This revision reflects slightly lower revenue growth expectations, partially offset by stronger profit margins and a marginally higher discount rate.Analyseartikel • Nov 08
Mankind Pharma Limited's (NSE:MANKIND) Earnings Haven't Escaped The Attention Of Investors
With a price-to-earnings (or "P/E") ratio of 53.4x Mankind Pharma Limited ( NSE:MANKIND ) may be sending very bearish...Narrative-Update • Sep 05
Chronic Therapy Demand And E-Commerce Will Fuel Future Expansion
With little change in both net profit margin and future P/E, there has been no effective revision to Mankind Pharma's consensus analyst price target, which remains at ₹2800. What's in the News Incorporated wholly owned subsidiary in Russia under the name Mankind Pharma LLC.Analyseartikel • Aug 03
Mankind Pharma Limited (NSE:MANKIND) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
The quarterly results for Mankind Pharma Limited ( NSE:MANKIND ) were released last week, making it a good time to...Analyseartikel • Jul 23
We Think You Should Be Aware Of Some Concerning Factors In Mankind Pharma's (NSE:MANKIND) Earnings
Mankind Pharma Limited's ( NSE:MANKIND ) robust recent earnings didn't do much to move the stock. We believe that...
Neues Narrative • Nov 12
Decisive Acquisition And Global Expansion Set To Revitalize Revenue Growth And Profitability
Strategic acquisitions and specialization in high-entry barrier segments are expected to enhance revenue growth and margins through synergies and R&D leverage.Aktionärsrenditen
| MANKIND | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | -1.3% | 0.7% | 0.3% |
| 1Y | -7.0% | 13.8% | -0.09% |
Rendite im Vergleich zur Industrie: MANKIND unter dem Niveau der Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 13.8% erzielte.
Rendite vs. Markt: MANKIND hinter dem Markt Indian zurück, der im vergangenen Jahr eine Rendite von -0.1 erzielte.
Preisvolatilität
| MANKIND volatility | |
|---|---|
| MANKIND Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.9% |
Stabiler Aktienkurs: MANKIND hatte in den letzten 3 Monaten im Vergleich zum Indian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: MANKINDDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1991 | 20,451 | Sheetal Arora | www.mankindpharma.com |
Mankind Pharma Limited entwickelt, produziert und vermarktet pharmazeutische Formulierungen und Produkte der Gesundheitsfürsorge hauptsächlich in Indien und international. Das Unternehmen entwickelt Arzneimittel für akute und chronische Therapien in den Bereichen Antiinfektiva, Herz-Kreislauf, Magen-Darm, Diabetes, Dermatologie, Schmerzen/Analgetika, Neuro/ZNS, Vitamine/Mineralien/Nährstoffe und Atemwegserkrankungen. Das Unternehmen bietet Produkte für die Gesundheitsfürsorge für Verbraucher an, wie z. B. Kondome, Schwangerschaftsnachweis-Sets, Notfallverhütungsmittel, Antazida-Pulver, Vitamin- und Mineralstoffpräparate und Mittel gegen Akne.
Mankind Pharma Limited's Grundlagenzusammenfassung
| MANKIND grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹1.04t |
| Gewinn(TTM) | ₹19.13b |
| Umsatz(TTM) | ₹142.78b |
54.1x
Kurs-Gewinn-Verhältnis 7.3x
Kurs-Umsatz-VerhältnisIst MANKIND zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| MANKIND Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹142.78b |
| Kosten der Einnahmen | ₹42.65b |
| Bruttogewinn | ₹100.13b |
| Sonstige Ausgaben | ₹81.00b |
| Gewinn | ₹19.13b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 46.32 |
| Bruttomarge | 70.13% |
| Nettogewinnspanne | 13.40% |
| Schulden/Eigenkapital-Verhältnis | 37.5% |
Wie hat sich MANKIND auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.08%
Aktuelle Dividendenrenditen/a
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/13 11:27 |
| Aktienkurs zum Tagesende | 2026/07/13 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Mankind Pharma Limited wird von 36 Analysten beobachtet. 20 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Ashwin Mehta | Ambit Capital |
| Gaurav Tinani | Ambit Capital |
| Pranav Chawla | Ambit Capital |